xepi ozenoxacin cream
medimetriks pharmaceuticals, inc. - ozenoxacin (unii: v0lh498rfo) (ozenoxacin - unii:v0lh498rfo) - ozenoxacin 10 mg in 1 g
zenoxone 1% cream
de pharmaceuticals - hydrocortisone - cutaneous cream - 10mg/1gram
zenocin cream
navana pharmaceuticals ltd. - ozenoxacin - cream - 10 mg/gm
ozanex cream
ferrer internacional, s.a. - ozenoxacin - cream - 1% - ozenoxacin 1% - antibiotics
xepi- ozenoxacin cream
cutanea life sciences, inc. - ozenoxacin (unii: v0lh498rfo) (ozenoxacin - unii:v0lh498rfo) - xepi™ is indicated for the topical treatment of impetigo due to staphylococcus aureus or streptococcus pyogenes in adult and pediatric patients 2 months of age and older [see clinical studies (14)] . none. risk summary there are no available data on the use of xepi in pregnant women to inform a drug associated risk. systemic absorption of xepi in humans is negligible following topical administration of xepi (up to twice the concentration of the marketed formulation) [see clinical pharmacology (12.3)] . due to the negligible systemic exposure, it is not expected that maternal use of xepi will result in fetal exposure to the drug. animal reproduction studies were not conducted with xepi. however, toxicity studies conducted in pregnant rats and rabbits administered the oral form of ozenoxacin showed no significant adverse developmental effects (at >10,000 times the maximum human plasma concentration seen with dermal application of ozenoxacin). the estimated background risk of major birth defects and miscarriag
xepi- ozenoxacin cream
biofrontera inc. - ozenoxacin (unii: v0lh498rfo) (ozenoxacin - unii:v0lh498rfo) - xepi™ is indicated for the topical treatment of impetigo due to staphylococcus aureus or streptococcus pyogenes in adult and pediatric patients 2 months of age and older [see clinical studies (14)] . none. risk summary there are no available data on the use of xepi in pregnant women to inform a drug associated risk. systemic absorption of xepi in humans is negligible following topical administration of xepi (up to twice the concentration of the marketed formulation) [see clinical pharmacology (12.3)] . due to the negligible systemic exposure, it is not expected that maternal use of xepi will result in fetal exposure to the drug. animal reproduction studies were not conducted with xepi. however, toxicity studies conducted in pregnant rats and rabbits administered the oral form of ozenoxacin showed no significant adverse developmental effects (at >10,000 times the maximum human plasma concentration seen with dermal application of ozenoxacin). the estimated background risk of major birth defects and miscarriag
ozadub 10 mg/g cream
ferrer internacional s.a. - ozenoxacin 10 mg/g - cream - 10 mg/g - ozenoxacin 10 mg/g - ozenoxacin
zenobloc-100 100mg film-coated tablet
n/a; importer: philgen pharmaceuticals inc.; distributor: philgen pharmaceuticals inc. - atenolol - film-coated tablet - 100mg
dubine 10 mg/g cream
ferrer internacional, s.a - ozenoxacin - cream - 10 milligram(s)/gram - other antibiotics for topical use
zenoxone 1% cream
teva uk ltd - hydrocortisone - cutaneous cream - 10mg/1gram